Serialized Label (51662 1317 1 Serialized Labeling Resized)
6% Hetastarch In 0.9% Sodium Chloride Injection, Solution
Product Images NDC 51662-1317
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for 6% Hetastarch In 0.9% Sodium Chloride (NDC 51662-1317). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Boxed Warning (Boxed Warning)
This is a warning against the use of hydroxyethyl starch products, particularly 6% Hetastarch in 0.9% Sodium Chloride Injection, in critically ill adult patients, including those suffering from sepsis. The use of these products increases the risk of mortality and the need for renal replacement therapy. Therefore, it is advised not to use HES products in these patients.*
Container (Container Label)
This is a description of a medication in a 500 mL container with NDC 0409-7248-13. The medication contains 6% Hetastarch in 0.9% Sodium Chloride Injection, and is meant for intravenous use only. Each 100 mL of the medication has Hetastarch, sodium chloride, water for injection, and sodium hydroxide for pH adjustment. The medication has electrolytes, with sodium 154 and chloride 154, with a total of 308 mOsmoL/L. The medication is sterile, non-pyrogenic, and a single-dose container. If administering through pressure infusion, all air should be withdrawn or expelled prior to infusion. The container should be discarded if unused, solutions should be clear, and the medication stored at 20-25°C (68-77°F), protected from freezing. The container should not have additives introduced into it. The medication contains DEHP Hospira and the manufacturer is Hospira, Inc. The text "300" and "400" are not relevant to the description.*
Structure (Description)
Boxed Warning (Highlights Boxed Warning)
This text contains a warning about the use of hydroxyethyl starch products, including 6% Hetastarch in 0.9% Sodium Chloride Injection, in critically ill adult patients, including those with sepsis. Use of these products increases the risk of mortality and renal replacement therapy. Therefore, it is not recommended to use HES products, such as 6% Hetastarch in 0.9% Sodium Chloride Injection, in critically ill adult patients including patients with sepsis.*
Dosage And Administration (Highlights D And A)
This text provides recommended dosages for adults undergoing leukapheresis, a medical procedure that involves the removal of white blood cells. The recommended dosage is between 500 to 1000 mL of the medication for adults. For leukapheresis, the recommended dosage is 250 to 700 mL of 6% Hetastarch in 0.9% Sodium Chloride Injection with citrate anticoagulant added to the input line of the centrifugation apparatus.*
How Supplied (How Supplied)
This is a product description for a flexible plastic container containing Hetastarch, with a unit of sale concentration of 30 g in 500 mL. The product is identified by its NDC code 0409-7248-03 and is also noted to contain 12 RIS (6 g Hetastarch/100 mL).*
Logo (Logo)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
